Evidence of off-target effects of bosutinib that promote retinoic acid-induced differentiation of non-APL AML cells

References

• De Vos S, Koeffler HP. Differentiation induction in leukemia and lymphoma. Nutrition Oncol. 2006:491
   Google Scholar
• Grignani F, Fagioli M, Alcalay M, et al. Acute promyelocytic leukemia: from genetics to treatment. 1994.
   Google Scholar
• Bunaciu RP, Yen A. Retinoid chemoprevention: who can benefit? Current Pharmacol Rep. 2015;1(6):391–400.
   PubMedGoogle Scholar
• Brown G, Hughes P. Retinoid differentiation therapy for common types of acute myeloid leukemia. Leuk Res Treatment. 2012;2012:1–11.
   Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–121.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Coutre SE. Optimizing therapy for acute myeloid leukemia. J National Compr Cancer Network. 2008;6(10):1003–1016.
   PubMedGoogle Scholar
• Al-Hussaini M, DiPersio JF. Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic. Expert Rev Hematol. 2014;7(4):439–464.
   PubMed Web of Science ®Google Scholar
• Johnson DE, Redner RL. An ATRActive future for differentiation therapy in AML. Blood Rev. 2015;29(4):263–268.
   PubMed Web of Science ®Google Scholar
• Warrell RJ. Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies, and implications [editorial; comment]. 1993.
   Google Scholar
• Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene. 2003;22(47):7305–7315.
   PubMed Web of Science ®Google Scholar
• Bunaciu RP, MacDonald RJ, Gao F, et al. Potential for subsets of wt-NPM1 primary AML blasts to respond to retinoic acid treatment. Oncotarget. 2018;9(3):4134.
   PubMedGoogle Scholar
• Iriyama N, Yuan B, Hatta Y, et al. Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation. Cancer Cell Int. 2016;16(1):1–11.
   PubMedGoogle Scholar
• Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene. 2004;23(48):7906–7909.
   PubMed Web of Science ®Google Scholar
• Kim M, Park SI, Kopetz S, et al. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res. 2009;335(1):249–259.
   PubMed Web of Science ®Google Scholar
• Johnson DE. Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis. Adv Enzyme Regul. 2008;48:98.
   PubMedGoogle Scholar
• Logue JS, Morrison DK. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev. 2012;26(7):641–650.
   PubMed Web of Science ®Google Scholar
• Superti-Furga G, Gonfloni S. A crystal milestone: the structure of regulated Src. Bioessays. 1997;19(6):447–450.
   PubMed Web of Science ®Google Scholar
• Sicheri F, Kuriyan J. Structures of Src-family tyrosine kinases. Curr Opin Struct Biol. 1997;7(6):777–785.
   PubMed Web of Science ®Google Scholar
• Kropf P, Wang L, Zang Y, et al. Dasatinib promotes ATRA-induced differentiation of AML cells. Leukemia. 2010;24(3):663–665.
   PubMed Web of Science ®Google Scholar
• Breitman T, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Nat Acad Sci. 1980;77(5):2936–2940.
   PubMed Web of Science ®Google Scholar
• Kikuchi H, Yuan BO, Nishimura Y, et al. Cytotoxicity of Vitex agnus-castus fruit extract and its major component, casticin, correlates with differentiation status in leukemia cell lines. Int J Oncol. 2013;43(6):1976–1984.
   PubMed Web of Science ®Google Scholar
• Collins SJ. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. 1987.
   Google Scholar
• Guerrouahen BS, Futami M, Vaklavas C, et al. Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res. 2010;16(4):1149–1158.
   PubMed Web of Science ®Google Scholar
• Isfort S, Crysandt M, Gezer D, et al. Bosutinib: a potent second-generation tyrosine kinase inhibitor. In: Small Molecules in Hematology. Cham: Springer; 2018:87–108.
   Google Scholar
• Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003;63(2):375–381.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Coutre PL, Piazza R. The role of bosutinib in the treatment of chronic myeloid leukemia. Future Oncol. 2020;16(2):4395–4408.
   PubMed Web of Science ®Google Scholar
• Keller-von Amsberg G, Koschmieder S. Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia. Onco Targets Ther. 2013;6:99.
   PubMed Web of Science ®Google Scholar
• Boschelli DH, Ye F, Wang YD, et al. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem. 2001;44(23):3965–3977.
   PubMed Web of Science ®Google Scholar
• Rashid A, Duan X, Gao F, et al. Roscovitine enhances all-trans retinoic acid (ATRA)-induced nuclear enrichment of an ensemble of activated signaling molecules and augments ATRA-induced myeloid cell differentiation. Oncotarget. 2020;11(12):1017–1036.
   PubMedGoogle Scholar
• Shen M, Yen A. c-Cbl interacts with CD38 and promotes retinoic acid–induced differentiation and G0 arrest of human myeloblastic leukemia cells. Cancer Res. 2008;68(21):8761–8769.
   PubMed Web of Science ®Google Scholar
• Bunaciu RP, Yen A. Activation of the Aryl hydrocarbon receptor ahr promotes retinoic acid–induced differentiation of myeloblastic leukemia cells by restricting expression of the stem cell transcription factor Oct4. Cancer Res. 2011;71(6):2371–2380.
   PubMed Web of Science ®Google Scholar
• Vultur A, Buettner R, Kowolik C, et al. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther. 2008;7(5):1185–1194.
   PubMed Web of Science ®Google Scholar
• MacDonald RJ, Bunaciu RP, Ip V, et al. Src family kinase inhibitor bosutinib enhances retinoic acid-induced differentiation of HL-60 leukemia cells. Leuk Lymphoma. 2018;59(12):2941–2951.
   PubMed Web of Science ®Google Scholar
• Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009;6(10):587–595.
   PubMed Web of Science ®Google Scholar
• Congleton J, Shen M, MacDonald R, et al. Phosphorylation of c-Cbl and p85 PI3K driven by all-trans retinoic acid and CD38 depends on Lyn kinase activity. Cell Signal. 2014;26(7):1589–1597.
   PubMed Web of Science ®Google Scholar
• Kazim N, Yen A. Role for Fgr and Numb in retinoic acid-induced differentiation and G0 arrest of non-APL AML cells. Oncotarget. 2021;12(12):1147–1164.
   PubMedGoogle Scholar
• Jensen HA, Bunaciu RP, Ibabao CN, et al. Retinoic acid therapy resistance progresses from unilineage to bilineage in HL-60 leukemic blasts. PloS One. 2014;9(6):e98929.
   PubMed Web of Science ®Google Scholar
• Congleton J, MacDonald R, Yen A. Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells. Leukemia. 2012;26(6):1180–1188.
   PubMed Web of Science ®Google Scholar
• Yen A, Varvayanis S, Smith JL, et al. Retinoic acid induces expression of SLP-76: expression with c-FMS enhances ERK activation and retinoic acid-induced differentiation/G0 arrest of HL-60 cells. Eur J Cell Biol. 2006;85(2):117–132.
   PubMed Web of Science ®Google Scholar
• Katzav S. Vav1: an oncogene that regulates specific transcriptional activation of T cells. Blood. 2004;103(7):2443–2451.
   PubMed Web of Science ®Google Scholar
• Bustelo XR. Regulatory and signaling properties of the Vav family. Mol Cell Biol. 2000;20(5):1461–1477.
   PubMed Web of Science ®Google Scholar
• Collins TL, Deckert M, Altman A. Views on Vav. Immunol Today. 1997;18(5):221–225.
   PubMedGoogle Scholar
• Bustelo XR. Vav family exchange factors: an integrated regulatory and functional view. Small GTPases. 2014;5(2):9.
   PubMedGoogle Scholar
• Wang J, Yen A. A MAPK-positive feedback mechanism for BLR1 signaling propels retinoic acid-triggered differentiation and cell cycle arrest. J Biol Chem. 2008;283(7):4375–4386.
   PubMed Web of Science ®Google Scholar
• Yen A, Williams M, Platko JD, et al. Expression of activated RAF accelerates cell differentiation and RB protein down-regulation but not hypophosphorylation. Eur J Cell Biol. 1994;65(1):103–113.
   PubMed Web of Science ®Google Scholar
• Yen A, Roberson MS, Varvayanis S, et al. Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res. 1998;58(14):3163–3172.
   PubMed Web of Science ®Google Scholar
• Katagiri K, Hattori S, Nakamura S, et al. Activation of Ras and formation of GAP complex during TPA-induced monocytic differentiation of HL-60 cells. 1994.
   Google Scholar
• Perez-Villar JJ, Whitney GS, Sitnick MT, et al. Phosphorylation of the linker for activation of T-cells by Itk promotes recruitment of Vav. Biochemistry. 2002;41(34):10732–10740.
   PubMed Web of Science ®Google Scholar
• Bertagnolo V, Brugnoli F, Mischiati C, et al. Vav promotes differentiation of human tumoral myeloid precursors. Exp Cell Res. 2005;306(1):56–63.
   PubMed Web of Science ®Google Scholar
• Ibabao CN, Bunaciu RP, Schaefer DMW, et al. The AhR agonist VAF347 augments retinoic acid-induced differentiation in leukemia cells. FEBS Open Bio. 2015;5(1):308–318.
   PubMedGoogle Scholar
• Tasseff R, Jensen HA, Congleton J, et al. An effective model of the retinoic acid induced HL-60 differentiation program. Sci Rep. 2017;7(1):1–21.
   PubMedGoogle Scholar
• Margolis B, Hu P, Katzav S, et al. Tyrosine phosphorylation of vav proto-oncogene product containing SH2 domain and transcription factor motifs. Nature. 1992;356(6364):71–74.
   PubMed Web of Science ®Google Scholar
• Abbas R, Hsyu P-H. Clinical pharmacokinetics and pharmacodynamics of bosutinib. Clin Pharmacokinet. 2016;55(10):1191–1204.
   PubMed Web of Science ®Google Scholar
• Elias D, Ditzel HJ. The potential of Src inhibitors. Aging (Albany Ny). 2015;7(10):734.
   PubMedGoogle Scholar
• Dos Santos C, Demur C, Bardet V, et al. A critical role for Lyn in acute myeloid leukemia. Blood J Am Soc Hematol. 2008;111(4):2269–2279.
   Google Scholar
• Shen M, Yen A. c-Cbl tyrosine kinase-binding domain mutant G306E abolishes the interaction of c-Cbl with CD38 and fails to promote retinoic acid-induced cell differentiation and G0 arrest. J Biol Chem. 2009;284(38):25664–25677.
   PubMed Web of Science ®Google Scholar
• MacDonald RJ, Shrimp JH, Jiang H, et al. Probing the requirement for CD38 in retinoic acid-induced HL-60 cell differentiation with a small molecule dimerizer and genetic knockout. Sci Rep. 2017;7(1):1–11.
   PubMedGoogle Scholar
• Smith J, Bunaciu RP, Reiterer G, et al. Retinoic acid induces nuclear accumulation of Raf1 during differentiation of HL-60 cells. Exp Cell Res. 2009;315(13):2241–2248.
   PubMed Web of Science ®Google Scholar
• Wallace AS, Supnick HT, Bunaciu RP, et al. RRD-251 enhances all-trans retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells. Oncotarget. 2016;7(29):46401.
   PubMedGoogle Scholar